| Identification | Back Directory | [Name]
Acetamide, N-[2-[3-[3-(2-aminoethoxy)propoxy]propoxy]ethyl]-2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]- | [CAS]
2435572-48-6 | [Synonyms]
Thalidomide-O-CONH-C2-O-(C3-O)2-NH2
N-(2-{3-[3-(2-aminoethoxy)propoxy]propoxy}ethyl)-2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]oxy}acetamide
Acetamide, N-[2-[3-[3-(2-aminoethoxy)propoxy]propoxy]ethyl]-2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]- | [Molecular Formula]
C25H34N4O9 | [MDL Number]
MFCD34469228 | [MOL File]
2435572-48-6.mol | [Molecular Weight]
534.56 |
| Hazard Information | Back Directory | [Uses]
Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology[1]. | [IC 50]
Cereblon | [References]
[1] Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine.?Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11. DOI:10.3389/fcell.2021.629326
[2] Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-1004. DOI:10.1016/S1473-3099(20)30638-1 |
|
|